¥192.48   ( %)
前日收盘: 当日成交量(股): 当日最高: 总股本:1536.66万
当日开盘: 当日成交额(元): 当日最低: 流通股本:
市盈率(动/静):0/0 市净率:0 市销率:0 总市值:29.58亿
52周最高:325.98 52周最低:38.82 转让方式: 单位:美元
$Madrigal Pharmaceuticals(MDGL)$
  • 还可以输入
  • 20016

Madrigal Pharmaceuticals(MDGL) 10月20日 02时14分

新闻 Research Report Identifies Brookfield Asset Management, Becton, Dickinson, IPG Photonics, ASML Holding N.V, American National Insurance, and Madrigal Pharmaceuticals with ......  url.vc.watch/Je7f
查看全文

Madrigal Pharmaceuticals(MDGL) 09月20日 07时26分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:MILLIGAN DAVID V
公告日:2018-09-19, 内部交易人:MILLIGAN DAVID V, 与发行人关系:/董事/, 操作码:M,20000(股)Common Stock; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-09-18, SEC Accession No. 0001179110-18-011555, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018011555/0001179110-18-011555-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 08月24日 21时53分

查看全文

Madrigal Pharmaceuticals(MDGL) 08月24日 21时53分

查看全文

Madrigal Pharmaceuticals(MDGL) 08月24日 21时53分

查看全文

Madrigal Pharmaceuticals(MDGL) 08月16日 06时32分

新闻 Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements Madrigal's MGL-3196 NASH abstract selected for oral presentat ......  url.vc.watch/jN6r
查看全文

Madrigal Pharmaceuticals(MDGL) 06月23日 07时09分

查看全文

Madrigal Pharmaceuticals(MDGL) 06月22日 09时24分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:BATE KENNETH
公告日:2018-06-21, 内部交易人:BATE KENNETH, 与发行人关系:/董事/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-19, SEC Accession No. 0001179110-18-008929, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008929/0001179110-18-008929-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月22日 07时32分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Levy Richard S
公告日:2018-06-21, 内部交易人:Levy Richard S, 与发行人关系:/董事/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-19, SEC Accession No. 0001179110-18-008928, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008928/0001179110-18-008928-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月22日 07时31分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:MILLIGAN DAVID V
公告日:2018-06-21, 内部交易人:MILLIGAN DAVID V, 与发行人关系:/董事/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-19, SEC Accession No. 0001179110-18-008927, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008927/0001179110-18-008927-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月22日 07时31分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Gollust Keith R
公告日:2018-06-21, 内部交易人:Gollust Keith R, 与发行人关系:/董事/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-19, SEC Accession No. 0001179110-18-008926, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008926/0001179110-18-008926-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月22日 07时31分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:CRAVES FRED B
公告日:2018-06-21, 内部交易人:CRAVES FRED B, 与发行人关系:/董事/10%持股人/, 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-19, SEC Accession No. 0001179110-18-008925, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008925/0001179110-18-008925-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月14日 06时43分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Schneebaum Marc R
公告日:2018-06-13, 内部交易人:Schneebaum Marc R, 与发行人关系:Chief Financial Officer/高管/, 操作:卖出,10099(股)Common Stock,均价$287.4600; 操作码:M,5223(股)Common Stock; 操作码:M,2734(股)Common Stock; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-11, SEC Accession No. 0001179110-18-008437, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008437/0001179110-18-008437-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月13日 11时07分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:CRAVES FRED B
公告日:2018-06-12, 内部交易人:CRAVES FRED B, 与发行人关系:/董事/10%持股人/, 操作:卖出,280000(股)Common Stock,均价$287.4600; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-11, SEC Accession No. 0001179110-18-008430, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008430/0001179110-18-008430-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月13日 11时07分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:FRIEDMAN PAUL A
公告日:2018-06-12, 内部交易人:FRIEDMAN PAUL A, 与发行人关系:Chief Executive Officer/董事/高管/, 操作:卖出,73526(股)Common Stock,均价$287.4600; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-11, SEC Accession No. 0001179110-18-008428, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008428/0001179110-18-008428-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月13日 11时07分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:Taub Rebecca
公告日:2018-06-12, 内部交易人:Taub Rebecca, 与发行人关系:Chief Medical Officer, EVP R&D/董事/高管/, 操作:卖出,73526(股)Common Stock,均价$287.4600; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-11, SEC Accession No. 0001179110-18-008426, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008426/0001179110-18-008426-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月13日 11时07分

公告 MADRIGAL PHARMACEUTICALS, INC. - SEC Form 4 - Statement of changes in beneficial ownership of securities:.内部交易 报告人:BAY CITY CAPITAL LLC
公告日:2018-06-12, 内部交易人:BAY CITY CAPITAL LLC, 与发行人关系:/董事/10%持股人/, 操作:卖出,280000(股)Common Stock,均价$287.4600; 本次交易含有相关衍生证券(puts, calls, warrants, options, convertible securities)的交易; 报告日:2018-06-11, SEC Accession No. 0001179110-18-008424, File:https://www.sec.gov/Archives/edgar/data/1157601/000117911018008424/0001179110-18-008424-index.htm $Madrigal Pharmaceuticals(MDGL)$
查看全文

Madrigal Pharmaceuticals(MDGL) 06月10日 14时31分

新闻 Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock
CONSHOHOCKEN, Pa., June 05, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: ......  url.vc.watch/giJx
查看全文

Madrigal Pharmaceuticals(MDGL) 06月10日 14时31分

新闻 Madrigal Pharmaceuticals Prices Public Offering of Common Stock
CONSHOHOCKEN, Pa., June 06, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a cli ......  url.vc.watch/giJ9
查看全文

Madrigal Pharmaceuticals(MDGL) 06月09日 11时15分

查看全文
  • 首页 上一页 1 2 3 下一页 尾页  每页20条/共55